Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECX-based chemotherapy in advanced HER2-negative gastric adenocarcinoma
2012-004126-17Phase 2Terminated
- Sponsor
- GOIM
- Start
- Jan 2013
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of capecitabine, cisplatin, epirubicin, docetaxel and oxaliplatin in gastric adenocarcinoma (3 arms), sponsored by GOIM. Primary endpoint: Objective response rate. Started Jan 2013; status: terminated.
02
Drugs
capecitabinecisplatinepirubicindocetaxeloxaliplatin
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on 2012-004126-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004126-17.